These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 37957054)

  • 1. Drug-induced cardiac toxicity and adverse drug reactions, a narrative review.
    Destere A; Merino D; Lavrut T; Rocher F; Viard D; Drici MD; Gérard AO
    Therapie; 2024; 79(2):161-172. PubMed ID: 37957054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cardiotoxicity as undesired side effect in the treatment of breast cancer].
    Gramatyka M
    Postepy Hig Med Dosw (Online); 2014 May; 68():483-97. PubMed ID: 24864100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toward a broader view of mechanisms of drug cardiotoxicity.
    Mamoshina P; Rodriguez B; Bueno-Orovio A
    Cell Rep Med; 2021 Mar; 2(3):100216. PubMed ID: 33763655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Chemotherapy-induced cardiotoxicity: Incidence, diagnosis and prevention].
    Nelson-Veniard M; Thambo JB
    Bull Cancer; 2015; 102(7-8):622-6. PubMed ID: 25935231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antineoplastic drugs inducing cardiac and vascular toxicity - An update.
    Barachini S; Ghelardoni S; Varga ZV; Mehanna RA; Montt-Guevara MM; Ferdinandy P; Madonna R
    Vascul Pharmacol; 2023 Dec; 153():107223. PubMed ID: 37678516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cardiac and vascular toxicity of chemotherapies].
    Ederhy S; Ancedy Y; Champiat S; Lopez-Trabada-Ataz D; Dulery R; Cohen A
    Rev Prat; 2018 Mar; 68(3):326-329. PubMed ID: 30869300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cardiotoxicity of chemotherapies].
    Castel M; Despas F; Modesto A; Gales C; Honton B; Galinier M; Senard JM; Pathak A
    Presse Med; 2013 Jan; 42(1):26-39. PubMed ID: 22727981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management.
    Curigliano G; Cardinale D; Dent S; Criscitiello C; Aseyev O; Lenihan D; Cipolla CM
    CA Cancer J Clin; 2016 Jul; 66(4):309-25. PubMed ID: 26919165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional and Transcriptional Characterization of Histone Deacetylase Inhibitor-Mediated Cardiac Adverse Effects in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
    Kopljar I; Gallacher DJ; De Bondt A; Cougnaud L; Vlaminckx E; Van den Wyngaert I; Lu HR
    Stem Cells Transl Med; 2016 May; 5(5):602-12. PubMed ID: 27034410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges and solutions in management of cardiotoxicity induced by checkpoint inhibitors.
    Mladosievičová B; Országhová Z; Jablonická M; Rečková M; Chovanec M; Mego M
    Klin Onkol; 2020; 33(5):350-355. PubMed ID: 33108879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of QT prolongation induced by anti-cancer drugs: Target therapy and old agents. Different algorithms for different drugs.
    Coppola C; Rienzo A; Piscopo G; Barbieri A; Arra C; Maurea N
    Cancer Treat Rev; 2018 Feb; 63():135-143. PubMed ID: 29304463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention.
    Pai VB; Nahata MC
    Drug Saf; 2000 Apr; 22(4):263-302. PubMed ID: 10789823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardionomics: a new integrative approach for screening cardiotoxicity of drug candidates.
    Gwathmey JK; Tsaioun K; Hajjar RJ
    Expert Opin Drug Metab Toxicol; 2009 Jun; 5(6):647-60. PubMed ID: 19442031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune Checkpoint Inhibitors and Cardiotoxicity: An Analysis of Spontaneous Reports in Eudravigilance.
    Mascolo A; Scavone C; Ferrajolo C; Rafaniello C; Danesi R; Del Re M; Russo A; Coscioni E; Rossi F; Alfano R; Capuano A
    Drug Saf; 2021 Sep; 44(9):957-971. PubMed ID: 34145536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical spectrum of anthracycline antibiotic cardiotoxicity.
    Bristow MR; Billingham ME; Mason JW; Daniels JR
    Cancer Treat Rep; 1978 Jun; 62(6):873-9. PubMed ID: 667861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical approaches to assess potential kinase inhibitor-induced cardiac toxicity: Past, present and future.
    Yang B; Papoian T
    J Appl Toxicol; 2018 Jun; 38(6):790-800. PubMed ID: 29369373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiotoxicity of cancer chemotherapy: implications for children.
    Simbre VC; Duffy SA; Dadlani GH; Miller TL; Lipshultz SE
    Paediatr Drugs; 2005; 7(3):187-202. PubMed ID: 15977964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Definition of hidden drug cardiotoxicity: paradigm change in cardiac safety testing and its clinical implications.
    Ferdinandy P; Baczkó I; Bencsik P; Giricz Z; Görbe A; Pacher P; Varga ZV; Varró A; Schulz R
    Eur Heart J; 2019 Jun; 40(22):1771-1777. PubMed ID: 29982507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors.
    Maurea N; Coppola C; Piscopo G; Galletta F; Riccio G; Esposito E; De Lorenzo C; De Laurentiis M; Spallarossa P; Mercuro G
    J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection():e19-e26. PubMed ID: 27755239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiotoxicity and Heart Failure: Lessons from Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes and Anticancer Drugs.
    Sachinidis A
    Cells; 2020 Apr; 9(4):. PubMed ID: 32316481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.